Market Performance - The Shanghai Composite Index experienced a slight decline of 0.09%, while the Shenzhen Component Index and the ChiNext Index fell by 0.85% and 0.91% respectively [1] - The total market turnover reached 3.28 trillion yuan, with over 1,600 stocks rising [1] Sector Highlights - The gold sector showed strong performance, with stocks such as Hunan Gold, Shengda Resources, Sichuan Gold, and China Gold hitting the daily limit [1] - Resource sectors including oil, coal, and gas were active, with stocks like Heshun Petroleum and Intercontinental Oil & Gas also reaching the daily limit [1] - The virus prevention concept saw a surge, with stocks like Maike Biological, Kaipu Biological, Zhijiang Biological, and Hualan Vaccine hitting the daily limit [1] Sector Declines - Sectors such as electric machinery, automotive parts, semiconductors, communication equipment, satellite internet, robotic actuators, and commercial aerospace experienced notable declines [1]

今日午后开盘，疫苗概念快速拉升，疫苗、生物医药、创新药等细分领域表现亮眼，截至发稿，疫苗 ETF富国（159645）盘中涨3.87%，其成分股华兰疫苗涨20%，万孚生物涨超17%，智飞生物涨超13%。 消息面上，华兰疫苗发布公告，公司重组带状疱疹疫苗于近日获得国家药品监督管理局颁发的药物临床 试验批准通知书，获准开展临床试验。该进展被视为公司在重要预防领域管线布局的关键突破。市场预 期随着国内老龄化进程加快，带状疱疹疫苗接种需求增长空间较大。 疫苗ETF富国（159645）紧密跟踪国证疫苗与生物科技指数（980015）指数，指数由业务涉及生物科技 产业的50家A股上市公司组成，反映A股市场的生物科技产业中优质上市公司的整体表现，帮助投资者 精准捕捉医疗疫苗领域投资机会。 （文章来源：每日经济新闻） 相关机构表示，长期来看，疫苗渗透率提升叠加人口老龄化进程加快，如带状疱疹疫苗接种需求增长空 间较大。而国内创新型疫苗的加速审批上市、鼓励疫苗研发投入加大等相关政策的陆续发布，也将推动 我国疫苗行业快速发展。此外，疫苗出海也为疫苗行业拓宽了需求领域，近期海外如印度西孟加拉邦暴 发尼帕病毒疫情也引发关注。 ...

Group 1 - Vaccine-related stocks have shown strong performance, with Zhifei Biological rising over 16%, Watson Bio increasing by more than 11%, and Kangtai Biological up by over 8% [1] - The vaccine-related ETFs have also experienced a rise of approximately 4% [1] Group 2 - Specific ETF performance includes: - Vaccine ETF from Fuguo at 0.727, up by 0.029 (4.15%) - Vaccine ETF from Penghua at 0.705, up by 0.028 (4.14%) - General Vaccine ETF at 0.642, up by 0.023 (3.72%) [2] - Institutions indicate that the long-term growth potential for vaccine demand is significant due to increasing vaccination penetration and an aging population [2] - The acceleration of approval and market entry for innovative domestic vaccines, along with increased investment in vaccine research and supportive policies, is expected to drive rapid development in China's vaccine industry [2]

Investment Rating - The report does not explicitly state an investment rating for the industry [2]. Core Insights - The pharmaceutical and biotechnology sector experienced a decline of 0.39% from January 19 to January 23, underperforming compared to the Wind All A index, which rose by 1.81% [3][8]. - Key segments such as offline pharmacies (up 9.66%), raw materials (up 2.41%), and pharmaceutical distribution (up 2.28%) showed positive performance, while medical R&D outsourcing (down 3.96%), chemical preparations (down 1.74%), and medical devices (down 0.7%) lagged behind [3][9]. - The personalized tumor vaccine is expected to trigger a significant shift in whole exome sequencing (WES) technology, with Moderna's mRNA personalized tumor vaccine showing a nearly 50% reduction in recurrence or death risk compared to Keytruda alone, based on five-year follow-up data [3][12]. - The report emphasizes the importance of high-quality WES data for the efficacy of mRNA personalized tumor vaccines, suggesting that once validated, WES will transition from an optional to a mandatory diagnostic tool, leading to a value reconstruction in the upstream sequencing industry [3][12]. Market Weekly Review - The pharmaceutical and biotechnology sector's performance from January 19 to January 23 showed a decline of 0.39%, underperforming the Wind All A index, which increased by 1.81% [8]. - Notable gainers included *ST Changyao (up 70.4%), Hualan Biological Engineering (up 32.2%), and Tianzhihang-U (up 27.7%), while major losers were Sunflower (down 37.5%), *ST Changyao (down 33.3%), and Luyuan Pharmaceutical (down 26.6%) [11][12]. Industry News and Key Company Announcements - On January 20, the National Healthcare Security Administration released guidelines for pricing medical services related to surgical and treatment auxiliary operations, which has garnered significant attention in the medical industry [11]. - Moderna and Merck announced that their personalized mRNA vaccine mRNA-4157, in combination with Keytruda, significantly improved recurrence-free survival in high-risk melanoma patients, reducing the risk of recurrence or death by 49% [12][13]. - GSK announced a $2.2 billion acquisition of RAPT Therapeutics, which includes a monoclonal antibody currently in clinical development for food allergies [15]. - The report highlights various companies' performance forecasts, including a projected net profit of -900 million to -995 million for Maiwei Bio, and a significant increase in revenue for JianKai Technology, with expected net profit growth of 101.09% to 121.20% [15][16].

Market Overview - As of January 26, A-shares showed mixed performance with the Shanghai Composite Index up by 0.12%, while the Shenzhen Component Index and the ChiNext Index fell by 0.74% and 0.86% respectively [1] - The trading volume in the Shanghai and Shenzhen markets reached 22,631 billion yuan, an increase of 3,495 billion yuan compared to the previous day [1] Gold and Precious Metals - International gold prices have surpassed $5,000 per ounce for the first time, leading to a surge in precious metals and non-ferrous resource stocks [2][4] - The price of spot gold increased by 1.87%, reaching a new historical high of $5,081 per ounce, with a monthly increase of over $730 [3] - Spot silver also saw a significant rise, exceeding $108 per ounce, with a monthly increase of over 50% [3] Companies in Precious Metals - Companies such as China Gold, Yuguang Gold Lead, and Silver Nonferrous Metals have experienced consecutive trading days of price increases, with China Gold rising by 9.98% [2][4] - The financial attributes of gold are being driven by factors such as real interest rates, the US dollar index, and geopolitical situations, with gold's foreign exchange reserve ratio increasing to 25.94% as of January 2026 [4] Space Photovoltaics - The space photovoltaic sector is gaining momentum, with companies like Mingyang Smart Energy experiencing a three-day consecutive price increase [5][6] - Elon Musk announced plans for SpaceX and Tesla to build a total of 200GW of photovoltaic capacity in the US over the next three years, which is expected to boost the sector [6] Influenza Vaccine Sector - The influenza vaccine sector is seeing strong performance, with companies like Zhijiang Biological and others hitting their price limits [7][8] - The rise is attributed to recent reports of Nipah virus infections in India, which have heightened demand for vaccines [8]

人民财讯1月26日电，沪指早间窄幅震荡，深证成指、创业板指走低。截至午间收盘，沪指涨0.12%， 深证成指跌0.74%，创业板指跌0.86%。盘面上，黄金概念持续走强，湖南黄金、盛达资源、四川黄 金、中国黄金等多股涨停；疫苗概念活跃，华兰疫苗20%涨停。此外，采掘、保险、有色金属、石油、 小金属、化肥等板块涨幅居前；航天航空、汽车零部件、游戏、半导体、家用轻工、商业航天、机器人 执行器概念等板块跌幅居前。全市场超1600只个股上涨，上午半天成交超2万亿元。 ...

Investment Rating - The industry investment rating is maintained at "Overweight" [2][8]. Core Insights - The vaccine industry is undergoing a transformation from scale expansion to innovation-driven growth, facing short-term pain due to supply-demand imbalance and homogenized competition, but the long-term growth logic remains intact, driven by policy, demand, and technology [8][25]. - Recent developments in vaccine research and international expansion signal positive trends, with a shift in focus from child vaccination to a broader lifecycle approach due to demographic changes [3][7]. Summary by Sections Industry Performance - The vaccine sector has seen a relative performance decline of 25% over the past 12 months compared to the CSI 300 index, with absolute returns down by 2% [3]. - The vaccine index rose by 0.49% in the last week, while the overall pharmaceutical sector declined by 0.39% [4][5]. Company Developments - Huashan Vaccine received approval for clinical trials of its recombinant shingles vaccine [3]. - Kanghua Bio announced a projected net profit decline of 41.55%-52.09% for 2025, primarily due to decreased vaccine sales and market competition [3]. - Kexing Bio secured a two-year exclusive order for hepatitis A vaccine in Oman, marking a significant breakthrough in the Middle East market [3]. - Aimee Vaccine's 20-valent pneumococcal polysaccharide conjugate vaccine has been approved for clinical trials [3]. Market Dynamics - The industry is experiencing a shift in demand dynamics, with a notable decrease in newborn population affecting vaccine demand negatively, necessitating a re-evaluation of growth strategies [3][7]. - The vaccine sector's price competition is intensifying due to a high proportion of Me-too products, leading to significant price drops for some vaccines [7][22]. Valuation Metrics - The vaccine sector's PE (ttm) stands at 93.89X, with a PB (lf) of 1.82X, indicating a slight increase in valuation metrics compared to previous periods [6][18]. Investment Recommendations - The report suggests focusing on companies with strong innovation capabilities and differentiated product lines, particularly those with high technical barriers and international market strategies [8][25]. - Long-term investment opportunities are seen in companies that can leverage innovation and international expansion to navigate current market challenges [7][8].

Core Viewpoint - The company announced a significant decline in net profit for 2025, attributed to industry policy adjustments and increased market competition affecting vaccine sales revenue [1] Financial Performance - The net profit attributable to shareholders is projected to be between 191 million to 233 million yuan, representing a year-on-year decrease of 41.55% to 52.09% [1] - The non-recurring net profit is expected to range from 208 million to 230 million yuan, reflecting a year-on-year decline of 49.73% to 54.54% [1] Revenue Impact - Vaccine sales revenue is anticipated to decrease by approximately 11% due to market competition and policy changes [1] - The company will not obtain overseas authorized phased revenue in 2025, which contributed 90 million yuan to profits in the same period last year [1] Future Reporting - Detailed financial performance will be disclosed in the company's 2025 annual report [1]

Core Viewpoint - Fosun Pharma announced a plan to spin off its subsidiary Fosun Antigen for a listing on the Hong Kong Stock Exchange, aiming to enhance financing channels and market competitiveness, despite the current downturn in the domestic vaccine industry and Fosun Antigen's poor financial performance [1][3]. Financial Performance - Fosun Antigen's revenue is projected to decline significantly from 461 million yuan in 2022 to 97.42 million yuan in 2024, with a net profit turning from a profit of 86.64 million yuan to a loss of 123.38 million yuan [3]. - The company's total assets as of December 31, 2024, are reported at 345.86 billion yuan, with a debt-to-asset ratio of 33.87% [3]. - The net cash flow from operating activities is negative at -105.29 million yuan for 2024, indicating financial strain [3]. Market Context - The domestic vaccine industry is currently facing challenges, with significant price competition among established products, leading to revenue declines for major players [6][9]. - The market for flu vaccines and rabies vaccines is particularly competitive, with price cuts from leading companies impacting overall sales [6][9]. Product Pipeline - Fosun Antigen has a limited product lineup, with four vaccines currently on the market, including rabies and flu vaccines, which are in a crowded market [5][6]. - The company is developing several vaccines, including the 13-valent and 24-valent pneumococcal conjugate vaccines, but lacks progress compared to competitors [7][10]. Competitive Landscape - The pneumococcal vaccine market is becoming increasingly competitive, with multiple players entering the space, leading to declining sales for existing products [9][12]. - Fosun Antigen's 24-valent pneumococcal vaccine is still in the early clinical trial phase, while competitors have advanced further in their development [10][12].

Core Viewpoint - Fosun Pharma is seeking new growth opportunities in the vaccine sector through the spin-off and listing of its vaccine platform, Fosun Antigen, on the Hong Kong Stock Exchange, which is seen as a strategic move to support independent development and capitalize on the revaluation of quality assets in the market [2][10]. Group 1: Spin-off and Financials - The spin-off plan announced on January 22 involves an initial issuance not exceeding 25% of the expanded total share capital of Fosun Antigen, which will remain a subsidiary of Fosun Pharma, reflecting its financial status in the consolidated financial statements [2][3]. - Fosun Antigen's projected revenues for 2022, 2023, and 2024 are 460 million yuan, 340 million yuan, and 97.42 million yuan respectively, with net profits of 86.64 million yuan, 11.35 million yuan, and a loss of 123.39 million yuan in 2024 [3][4]. Group 2: Market Potential and Competition - The global vaccine market is experiencing rapid expansion, with a size of $77 billion in 2023 and a compound annual growth rate (CAGR) of 15% from 2019 to 2023. The Chinese vaccine market (excluding COVID-19 vaccines) is expected to reach approximately 101.77 billion yuan in 2024, growing to 300 billion yuan by 2035, with an annual growth rate of about 12% [4][5]. - The Chinese vaccine market has significant growth potential, particularly in rabies and influenza vaccines, where current vaccination rates are low, indicating room for increased demand [5][6]. Group 3: Competitive Advantages and Challenges - Fosun Antigen has established a diverse range of vaccine products, including rabies and influenza vaccines, and is developing high-end products like the 13-valent pneumococcal conjugate vaccine, which is currently in Phase III clinical trials [6][7]. - The domestic vaccine market is characterized by moderate competition compared to the pharmaceutical market, with over 40 vaccine manufacturers. The focus is on collaboration to enhance market size and vaccination rates rather than engaging in cutthroat competition [5][8]. Group 4: Future Outlook - The spin-off of Fosun Antigen is part of Fosun Pharma's broader strategy to optimize asset structure and unlock the value of its subsidiaries, with previous successful spin-offs providing a framework for this move [10][11]. - The future of the vaccine market is expected to be competitive, especially in the pneumococcal vaccine sector, where established players like Pfizer dominate. The rapid development of mRNA vaccine technology poses additional challenges for traditional vaccine companies [10][11].